Pionyr Immunotherapeutics
Myeloid tuning therapeutics

Pionyr Immunotherapeutics (formerly Precision Immune Inc.) is developing cancer immunotherapies that target the tumor microenvironment to enhance the body’s antitumor immunity. The company is exploiting novel target discovery and antibody generation platform technologies to create the next generation of immuno-oncology therapeutics. Their technology is based on the discovery that altering the tumor microenvironment to favor immune-activating cells over immune-suppressing cells enhances the body’s ability to combat cancer.


University
UC San Francisco
Sector
Life Science
Status
Active
Initial Investment Stage
Early
View Website